| Literature DB >> 29085218 |
Jing-Xian Sun1, Ke-Yun Bai1, Yan-Feng Liu2, Gang Du2, Zhi-Hao Fu2, Hao Zhang2, Jin-Huan Yang2, Ben Wang2, Xiu-Yu Wang3, Bin Jin4.
Abstract
AIM: To prospectively evaluate the effect of local wound infiltration with ropivacaine on postoperative pain relief and stress response reduction after open hepatectomy.Entities:
Keywords: Local wound infiltration; Open hepatectomy; Postoperative pain; Ropivacaine; Surgical stress
Mesh:
Substances:
Year: 2017 PMID: 29085218 PMCID: PMC5643294 DOI: 10.3748/wjg.v23.i36.6733
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Demographic characteristics of the patients studied (mean ± SD)
| Age (yr) | 48.38 ± 11.74 | 49.59 ± 12.42 | -0.36 | 0.7176 |
| Gender | ||||
| Male/female | 18/8 | 18/9 | 0.04 | 0.8415 |
| Weight (kg) | 63.04 ± 9.21 | 66.04 ± 9.86 | -1.14 | 0.2583 |
| ASA grade | ||||
| I/II/III | 4/17/5 | 7/15/5 | 0.92 | 0.6298 |
| Incision length (cm) | 24.65 ± 1.83 | 24.22 ± 2.76 | 0.67 | 0.5075 |
| Operation type | ||||
| Left hepatectomy | 8 | 5 | 0.0086 | |
| Right hepatectomy | 13 | 8 | ||
| Mesohepatectomy | 1 | 0 | ||
| Caudate lobectomy | 2 | 1 | ||
| Irregular hepatectomy | 2 | 13 | ||
| Postoperative pathology | ||||
| Hepatocellular carcinoma | 22 | 18 | 0.3292 | |
| Intra-and extrahepatic cholangiolithiasis | 3 | 7 | ||
| Hepatic focal nodular hyperplasia | 1 | 1 | ||
| Hepatocellular adenoma | 0 | 1 |
ASA: American Society of Anesthesiologists.
Figure 1Visual analogue scale scores at rest and on movement, mean arterial pressure, and heart rate during the first 48 h after surgery. A: VAS scores at rest; B: VAS scores on movement; C: MAP; D: HR. aP < 0.05; bP < 0.001; cP < 0.0001. VAS: Visual analogue scale; MAP: Mean arterial pressure; HR: Heart rate.
Visual analog scale scores at rest and on movement, mean arterial pressure, heart rate, and cumulative sufentanil consumption
| VAS at rest | |||||
| Ropivacaine group | 2.38 ± 0.50 | 2.27 ± 0.45 | 2.04 ± 0.20 | 2.12 ± 0.33 | 2.08 ± 0.27 |
| Control group | 2.78 ± 0.58 | 2.67 ± 0.48 | 2.48 ± 0.51 | 2.22 ± 0.42 | 2.15 ± 0.36 |
| -2.65 | -3.17 | -4.21 | -1.03 | -0.81 | |
| 0.0106 | 0.0032 | 0.0002 | 0.3096 | 0.4230 | |
| VAS on movement | |||||
| Ropivacaine group | 3.27 ± 0.53 | 3.35 ± 0.63 | 3.31 ± 0.62 | 3.23 ± 0.43 | 3.11 ± 0.52 |
| Control group | 3.63 ± 0.56 | 3.85 ± 0.60 | 3.78 ± 0.64 | 3.41 ± 0.57 | 3.30 ± 0.47 |
| -2.39 | -2.99 | -2.72 | -1.27 | -1.34 | |
| 0.0208 | 0.0043 | 0.0089 | 0.2110 | 0.1857 | |
| MAP (mmHg) | |||||
| Ropivacaine group | 95.88 ± 5.08 | 93.35 ± 4.63 | 92.62 ± 4.43 | 94.73 ± 4.16 | 93.19 ± 3.41 |
| Control group | 97.74 ± 4.17 | 96.15 ± 4.14 | 97.56 ± 4.23 | 98.37 ± 3.99 | 94.89 ± 3.90 |
| -1.46 | -2.32 | -4.16 | -3.25 | -1.69 | |
| 0.1515 | 0.0241 | 0.0001 | 0.0020 | 0.0981 | |
| HR (bpm) | |||||
| Ropivacaine group | 88.96 ± 4.12 | 90.19 ± 3.92 | 89.73 ± 4.45 | 91.65 ± 4.30 | 90.31 ± 4.45 |
| Control group | 92.04 ± 4.27 | 93.41 ± 4.62 | 94.74 ± 3.88 | 94.56 ± 3.43 | 92.11 ± 4.05 |
| -2.66 | -2.73 | -4.37 | -2.72 | -1.54 | |
| 0.0103 | 0.0087 | < 0.0001 | 0.0089 | 0.1289 | |
| Cumulative sufentanil consumption (μg) | |||||
| Ropivacaine group | 0 | 14.94 ± 2.56 | 30.40 ± 5.39 | 56.75 ± 6.20 | 83.02 ± 7.05 |
| Control group | 0 | 17.06 ± 3.81 | 35.50 ± 6.91 | 65.31 ± 7.09 | 91.39 ± 7.34 |
| -2.36 | -2.99 | -4.67 | -4.23 | ||
| 0.0220 | 0.0043 | < 0.0001 | < 0.0001 |
As to cumulative sufentanil consumption, the time point was set at 36 h. VAS: Visual analog scale; MAP: Mean arterial pressure; HR: Heart rate.
Figure 2Plasma levels of epinephrine, norepinephrine and cortisol and cumulative sufentanil consumption during the first 48 h after surgery. A: Epinephrine; B: Norepinephrine; C: Cortisol; and D: Cumulative sufentanil consumption. aP < 0.05; cP < 0.0001.
Plasma concentrations of epinephrine, norepinephrine and cortisol (pg/mL)
| Epinephrine | |||
| Ropivacaine group | 64.19 ± 19.62 | 86.54 ± 28.64 | 94.27 ± 30.10 |
| Control group | 66.19 ± 20.30 | 110.26 ± 31.88 | 118.59 ± 33.65 |
| -0.36 | -2.85 | -2.77 | |
| 0.7180 | 0.0064 | 0.0078 | |
| Norepinephrine | |||
| Ropivacaine group | 251.31 ± 30.19 | 280.62 ± 34.22 | 310.12 ± 35.15 |
| Control group | 259.70 ± 31.72 | 361.00 ± 36.06 | 390.41 ± 37.73 |
| -0.99 | -8.32 | -8.01 | |
| 0.3286 | < 0.0001 | < 0.0001 | |
| Cortisol | |||
| Ropivacaine group | 342.00 ± 33.72 | 391.81 ± 36.53 | 450.62 ± 39.39 |
| Control group | 331.59 ± 31.92 | 487.48 ± 34.36 | 518.85 ± 38.21 |
| 1.15 | -9.82 | -6.40 | |
| 0.2537 | < 0.0001 | < 0.0001 |
Time to bowel recovery, postoperative nausea and vomiting, and hospitalization length in the two groups
| Time to bowel recovery (d) | 3.15 ± 1.01 | 3.93 ± 1.17 | -2.56 | 0.0133 |
| PONA | ||||
| No PONA | 7 | 3 | 0.2729 | |
| Nausea without vomiting | 16 | 18 | ||
| Nausea with vomiting | 3 | 6 | ||
| Hospitalization (d) | 8.65 ± 2.43 | 10.52 ± 3.49 | -2.25 | 0.0289 |
PONA: Postoperative nausea and vomiting.